Yamanouchi Pharmaceutical Company Ltd.

Tadayoshi Ohmura

Hiroitsu Kawata

Satoru Yoneya

Masayoshi Aruga

Takashi Sonobe

Hiroshi Sugiura

Chiharu Sone

Muneo Fukui

Atsushi Kajiyama

Shunji Hasumi

Hiroitsu Kawada

Katsuhiko Yano

Toshiharu Hosono

Yukio Kubota

Masuo Murakami

Yutaka Konno

Jun Sekino

Kiyoshi Okazaki

Hidemi Shimizu

Toshimitsu Konno

Hiroyoshi Shiozawa

Shigeru Yamazaki

Saburo Higuchi

Yoshiaki Soeishi

Ken Iwai

Munetaka Hattori

Yasuhiro Nishizono

Mikio Matsumura

Seiki Tashiro

Chiharu Yamada

Quick-dissolution solid preparation

A coating material for controlling drug release, useful for long acting formulations--e.g. for once-a-day administration, and to a long acting granular composition comprising a drug (especially one conventionally difficult to prepare in long acting form) coated with the coating material. This composition may be mixed with other granular drug formulations. The drug-release controlling coating material comprising, in a specific ratio, one specific water-insoluble and low water-permeability polymers and two materials differing from each other in the pH-dependency of their solubility (pH-dependent polymer-materials).

Drug release controlling coating material for long acting formulations

A coating material for controlling drug release, useful for long acting formulations--e.g. for once-a-day administration, and to a long acting granular composition comprising a drug (especially one conventionally difficult to prepare in long acting form) coated with the coating material. This composition may be mixed with other granular drug formulations. The drug-release controlling coating material comprising, in a specific ration, one specific water-insoluble and low water-permeability polymers and two materials differing from each other in the pH-dependency of their solubility (pH-dependent polymer-materials).

Drug-release controlling coating material for long acting formulations

A spherical pellet like composition of nicardipine composed of small granular nuclei such as sugar particles coated with amorphous nicardipine or a salt thereof, a pH-dependent additive and a surface active agent. The spherical pellet like composition of nicardipine may have a further coating of a medicament permeating material as an outermost coating. The spherical pellet like composition may be mixed with the spherical pellet like composition coated with the medicament permeating material.

Composition for long acting nicardipine preparation and process of

Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material in nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).

Sustained release pharmaceutical composition of solid medical material

An oily composition of an antitumor drug comprising at least one sparingly oil soluble or water-soluble antitumor drug, at least one fat or oil, and at least one solubilizing adjuvant in an oily vehicle selected from the group consisting of crown ether, lecithin, polyethylene glycol, propylene glycol, vitamin E, polyoxyethylene alkylether, and sucrose esters of fatty acids.

Oily compositions of antitumor drugs

A novel nifedipine-containing solid pharmaceutical preparation composition comprising a mixture of nifedipine and at least one 1st(a) substance selected from polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; a mixture of nifedipine, at least one 1st(b) substance selected from polyvinyl pyrrolidone, urea, citric acid mannitol, succinic acid, methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and amino acid, and at least one 2nd substance selected from a surface active agent, polyethylene glycol, propylene glycol, glycerol, a glycerol fatty acid ester and a vegetable oil; or a mixture of nifedipine, the 1st(b) substance, the 2nd substance and calcium lactate. The composition of this invention can increase the bioavailability of nifedipine and makes it possible to provide a nifedipine-containing pharmaceutical preparation which has small bulk and can be easily administered.

Nifedipine-containing solid preparation composition

Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).

Sustained release pharmaceutical composition of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment): and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).

A novel coating agent for solid medicaments containing a hydrogel-like substance of a water-insoluble hydroxypropyl cellulose having 5-16% by weight of a hydroxypropoxy group or the dry powder of a hydrogel-like substance. By coating solid medicaments with the coating agent, solid medicaments having high impact resistance and showing very less aging can be provided advantageously in industry.

Coating agents for solid medicaments

A dried and stabilized prostaglandin composition containing a prostaglandin E group compound with calcium lactate and/or amylopectin, and a stabilized pharmaceutical preparation for practical administration prepared from the said composition.

Stabilized prostaglandin composition and the process for the preparation

A single phase solid composition wherein one part of a non-aqueous liquid and 0.5-6 parts of calcium lactate hydrate are mixed and heated. The product according to this invention is very stable and can be formed into various kinds of moldings by a simple operation so that it may be applied to many uses.

Growing community of inventors

Niiza, Japan

Tadayoshi Ohmura